Chilton Capital Management LLC Purchases 137,531 Shares of Gilead Sciences, Inc. $GILD

Chilton Capital Management LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 58.4% during the second quarter, Holdings Channel reports. The firm owned 372,849 shares of the biopharmaceutical company’s stock after purchasing an additional 137,531 shares during the quarter. Gilead Sciences comprises about 1.5% of Chilton Capital Management LLC’s holdings, making the stock its 20th biggest position. Chilton Capital Management LLC’s holdings in Gilead Sciences were worth $41,338,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC increased its holdings in Gilead Sciences by 4.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 362,516 shares of the biopharmaceutical company’s stock worth $40,192,000 after acquiring an additional 16,947 shares in the last quarter. Resonant Capital Advisors LLC grew its holdings in shares of Gilead Sciences by 11.5% in the second quarter. Resonant Capital Advisors LLC now owns 21,078 shares of the biopharmaceutical company’s stock valued at $2,337,000 after purchasing an additional 2,169 shares in the last quarter. Wealthfront Advisers LLC increased its holdings in shares of Gilead Sciences by 16.3% in the 2nd quarter. Wealthfront Advisers LLC now owns 248,854 shares of the biopharmaceutical company’s stock worth $27,590,000 after buying an additional 34,942 shares during the last quarter. Oppenheimer Asset Management Inc. increased its position in shares of Gilead Sciences by 3.6% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 129,697 shares of the biopharmaceutical company’s stock valued at $14,380,000 after purchasing an additional 4,565 shares during the last quarter. Finally, Darden Wealth Group Inc boosted its stake in shares of Gilead Sciences by 4.6% during the 2nd quarter. Darden Wealth Group Inc now owns 4,639 shares of the biopharmaceutical company’s stock worth $514,000 after purchasing an additional 206 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $295,200.00. Following the completion of the sale, the chief financial officer directly owned 157,055 shares of the company’s stock, valued at $18,545,054.40. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $354,240.00. Following the transaction, the insider directly owned 110,193 shares in the company, valued at $13,011,589.44. The trade was a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 71,500 shares of company stock worth $8,281,540. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Up 0.2%

Shares of Gilead Sciences stock opened at $120.94 on Friday. Gilead Sciences, Inc. has a 1 year low of $86.08 and a 1 year high of $124.61. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The company’s fifty day moving average is $115.47 and its two-hundred day moving average is $111.07. The company has a market capitalization of $150.06 billion, a P/E ratio of 24.09, a PEG ratio of 0.83 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same period last year, the firm earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s payout ratio is presently 62.95%.

Wall Street Analyst Weigh In

GILD has been the topic of several research analyst reports. The Goldman Sachs Group increased their price objective on Gilead Sciences from $105.00 to $108.00 and gave the stock a “neutral” rating in a research note on Friday, October 17th. TD Cowen upped their target price on Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday. Royal Bank Of Canada increased their price target on Gilead Sciences from $98.00 to $100.00 and gave the stock a “sector perform” rating in a research report on Wednesday, October 8th. BMO Capital Markets lifted their price target on Gilead Sciences from $130.00 to $135.00 and gave the company an “outperform” rating in a research note on Monday, October 20th. Finally, Citigroup lifted their price objective on Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $122.61.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.